Inflammatory Pain ' Pipeline Review, H1 2013

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Inflammatory Pain ' Pipeline Review, H1 2013
Published on February 2013

Report Summary


Summary

Global Markets Direct's, 'Inflammatory Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline.
This report provides information on the therapeutic development for Inflammatory Pain, complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory
Pain. Inflammatory Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's
proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Inflammatory Pain.
- A review of the Inflammatory Pain products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Inflammatory Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Inflammatory Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Inflammatory Pain pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Inflammatory Pain ' Pipeline Review, H1 2013 (From Slideshare) Page 1/11


Table of Content

Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Inflammatory Pain Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Inflammatory Pain 12
Inflammatory Pain Therapeutics under Development by Companies 14
Inflammatory Pain Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Early Clinical Stage Products 21
Discovery and Pre-Clinical Stage Products 22
Inflammatory Pain Therapeutics ' Products under Development by Companies 23
Inflammatory Pain Therapeutics ' Products under Investigation by Universities/Institutes 26
Companies Involved in Inflammatory Pain Therapeutics Development 27
Boehringer Ingelheim GmbH 27
Shionogi & Co., Ltd. 28
MedImmune LLC 29
Takeda Pharmaceutical Company Limited 30
Glenmark Pharmaceuticals Ltd. 31
Teva Pharmaceutical Industries Limited 32
Evotec Aktiengesellschaft 33
Anavex Life Sciences Corp. 34
CombinatoRx, Incorporated 35
Array BioPharma Inc. 36
Pluristem Therapeutics Inc. 37
Proximagen Neuroscience plc. 38
Newron Pharmaceuticals S.p.A. 39
Angelini Group 40
BCN Peptides S.A. 41
Palau Pharma S.A 42
Probiodrug AG 43
AngioChem Inc. 44
Hydra Biosciences, Inc. 45
NeurAxon, Inc. 46
CBio Limited 47



Winston Pharmaceuticals, Inc. 48
NeuroTherapeutics Pharma Inc. 49
Spinifex Pharmaceuticals Pty Limited 50
RaQualia Pharma Inc. 51
Inflammatory Pain ' Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
P2X3 and P2X2/3 Antagonist - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
PMX-53 - Drug Profile 58
R&D Progress 58
OX-MPI - Drug Profile 60
R&D Progress 60
nNOS/iNOS - Drug Profile 61
R&D Progress 61
HC-030031 - Drug Profile 62
R&D Progress 62
ralfinamide - Drug Profile 64
R&D Progress 64
TASS - Drug Profile 65
R&D Progress 65
Z-160 - Drug Profile 66
R&D Progress 66
RQ-00203066 - Drug Profile 68
R&D Progress 68
zucapsaicin Intra-articular - Drug Profile 69



R&D Progress 69
TrkA Program - Drug Profile 70
R&D Progress 70
XToll - Drug Profile 71
R&D Progress 71
ANAVEX-1079 - Drug Profile 73
R&D Progress 73
ANG-2002 - Drug Profile 74
R&D Progress 74
AMAP-102 - Drug Profile 75
R&D Progress 75
AF-3485 - Drug Profile 77
R&D Progress 77
R&D Progress 78
Nav 1.7 Blocker Program - Drug Profile 79
R&D Progress 79
GRC-17536 - Drug Profile 80
R&D Progress 80
GBR-900 - Drug Profile 81
R&D Progress 81
CDK9-inhibitors - Drug Profile 82
R&D Progress 82
CNSB-002 - Drug Profile 83



R&D Progress 83
CNSB-006 - Drug Profile 84
R&D Progress 84
PLX For Neuropathic and Inflammatory Pain - Drug Profile 85
R&D Progress 85
Z-944 - Drug Profile 86
R&D Progress 86
THA-902 - Drug Profile 87
R&D Progress 87
THA-903 - Drug Profile 88
R&D Progress 88
RAP-103 - Drug Profile 89
R&D Progress 89
Nav1.8 Sodium Channel Blocker - Drug Profile 90
R&D Progress 90
Nav1.3 Sodium Channnel Blocker - Drug Profile 91
R&D Progress 91
R&D Progress 92
minocycline - Drug Profile 94
R&D Progress 94
Neogenius Project - Drug Profile 95
R&D Progress 95
Project MITRA - Drug Profile 97



R&D Progress 97
NTP Compound For Inflammatory Pain - Drug Profile 98
R&D Progress 98
Neuroscience Program - Drug Profile 99
R&D Progress 99
Drug For Neuroscience - Drug Profile 100
R&D Progress 100
Cannabinoid Receptor Agonists - Drug Profile 101
R&D Progress 101
DD-04107 - Drug Profile 102
R&D Progress 102
S-120083 - Drug Profile 103
S-120083 acts by undisclosed mechanism of action. 103
R&D Progress 103
AR-786 - Drug Profile 104
R&D Progress 104
AT2 Receptor Antagonist - Drug Profile 105
R&D Progress 105
Drug For Inflammatory Pain - Drug Profile 106
R&D Progress 106
ZJ-43 - Drug Profile 107
R&D Progress 107
Ion Channel Antagonist - Drug Profile 109
R&D Progress 109
Glutaminase Inhibitor - Drug Profile 110



R&D Progress 110
Inflammatory Pain Therapeutics ' Drug Profile Updates 111
Inflammatory Pain Therapeutics ' Discontinued Products 118
Inflammatory Pain Therapeutics - Dormant Products 119
Inflammatory Pain ' Product Development Milestones 121
Featured News & Press Releases 121
Jul 10, 2012: Zalicus Initiates Phase I Multiple Ascending Dose Study With Z944 121
Jun 19, 2012: Zalicus Successfully Completes Phase I Single Ascending Dose Study With Z944 121
Feb 15, 2012: Zalicus Publishes Preclinical Data Of New Ion Channel Compound, Z944 In Science Translational Medicine 122
Dec 19, 2011: Zalicus Initiates Phase I Clinical Trial Of Z944 122
Oct 31, 2010: BCN PEPTIDES And DIVERDRUGS Announce Results Of DD04107, A New Class Of Non-Opioid Analgesics 122
Aug 09, 2010: Pluristem's PLX Cells Found To Be Effective In Treating Neuropathic And Inflammatory Pain 123
Jan 28, 2010: ChemoCentryx Initiates Phase I Clinical Trial Of CCX168 124
Mar 12, 2009: Glenmark's GRC 15300 To Enter Phase I Trials 124
Jan 24, 2009: Glenmark Pharma To Develop GRC 15300 125
Apr 07, 2008: Biovitrum's BVT.115959 Is Very Safe And Shows Positive Effect 125
Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 127
Disclaimer 127

List of Tables

Number of Products Under Development for Inflammatory Pain, H1 2013 12
Products under Development for Inflammatory Pain ' Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Development by Companies, H1 2013 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Development by Companies, H1 2013 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2013 26
Boehringer Ingelheim GmbH, H1 2013 27
Shionogi & Co., Ltd., H1 2013 28



MedImmune LLC, H1 2013 29
Takeda Pharmaceutical Company Limited, H1 2013 30
Glenmark Pharmaceuticals Ltd., H1 2013 31
Teva Pharmaceutical Industries Limited, H1 2013 32
Evotec Aktiengesellschaft, H1 2013 33
Anavex Life Sciences Corp., H1 2013 34
CombinatoRx, Incorporated, H1 2013 35
Array BioPharma Inc., H1 2013 36
Pluristem Therapeutics Inc., H1 2013 37
Proximagen Neuroscience plc., H1 2013 38
Newron Pharmaceuticals S.p.A., H1 2013 39
Angelini Group, H1 2013 40
BCN Peptides S.A., H1 2013 41
Palau Pharma S.A, H1 2013 42
Probiodrug AG, H1 2013 43
AngioChem Inc., H1 2013 44
Hydra Biosciences, Inc., H1 2013 45
NeurAxon, Inc., H1 2013 46
CBio Limited, H1 2013 47
Winston Pharmaceuticals, Inc., H1 2013 48
NeuroTherapeutics Pharma Inc., H1 2013 49
Spinifex Pharmaceuticals Pty Limited, H1 2013 50
RaQualia Pharma Inc., H1 2013 51
Assessment by Monotherapy Products, H1 2013 52
Assessment by Stage and Route of Administration, H1 2013 54
Assessment by Stage and Molecule Type, H1 2013 56
Inflammatory Pain Therapeutics ' Drug Profile Updates 111
Inflammatory Pain Therapeutics ' Discontinued Products 118
Inflammatory Pain Therapeutics ' Dormant Products 119
Inflammatory Pain Therapeutics ' Dormant Products (Contd..1) 120

List of Figures

Number of Products under Development for Inflammatory Pain, H1 2013 12
Products under Development for Inflammatory Pain ' Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Discovery and Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 52
Assessment by Route of Administration, H1 2013 53
Assessment by Stage and Route of Administration, H1 2013 54
Assessment by Molecule Type, H1 2013 55
Assessment by Stage and Molecule Type, H1 2013 56


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Inflammatory Pain ' Pipeline Review, H1 2013

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Mehr von ReportLinker.com

Mehr von ReportLinker.com (20)

Inflammatory Pain ' Pipeline Review, H1 2013